SHINE

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease

Retrieved on: 
Monday, April 22, 2024
Amyloid, Alzheimer's disease, Jort, University, MCI, Inflammation, Oxidative stress, ARIA, News, Research, Neuroinflammation, Cognition, Doctor of Philosophy, ADAS, START, KOL, Patient, SHINE, Perception, Neuron, Antibody, Therapy, Plaque, Cerebrospinal fluid

“The KOL roundtable we conducted featured a panel of Alzheimer’s disease expert clinicians and researchers who highlighted the need to find Alzheimer’s disease treatments that are less burdensome for patients and their care partners,” said Lisa Ricciardi, Cognition’s president and CEO .

Key Points: 
  • “The KOL roundtable we conducted featured a panel of Alzheimer’s disease expert clinicians and researchers who highlighted the need to find Alzheimer’s disease treatments that are less burdensome for patients and their care partners,” said Lisa Ricciardi, Cognition’s president and CEO .
  • The SHINE study enrolled participants in the U.S. and several countries in Europe including The Netherlands.
  • Dr. Vijverberg reviewed the design of the SHINE study and the results of the preliminary analysis of the first 24 patients who finished six months of treatment.
  • An archive of the KOL roundtable discussion is available on the News & Events page of the Investors section of the Cognition website or may be accessed directly at the following URL: https://lifescievents.com/event/cognition/ .

Hexagon revolutionises robotic quality inspection with highly flexible and scalable PRESTO System

Retrieved on: 
Monday, April 22, 2024
Nexus, UL, Safety, OOT, 3D, Automation, SHINE, QMS, Quality management system, CE, 3D printing

PRESTO System builds on the foundation of its turnkey PRESTO quality inspection cell to provide manufacturers a future-proof system that sets a new standard for scalable, versatile, and seamlessly integrated automated quality inspection.

Key Points: 
  • PRESTO System builds on the foundation of its turnkey PRESTO quality inspection cell to provide manufacturers a future-proof system that sets a new standard for scalable, versatile, and seamlessly integrated automated quality inspection.
  • PRESTO System empowers manufacturers to become more agile with automated robotic programming that enables a single quality control specialist to create, test and deploy robust robotic inspection in hours.
  • The modularity of the PRESTO System provides flexible deployment, enabling manufacturers to rapidly scale their quality inspection capacity in alignment with their business needs.
  • This ensures consistent performance and simplifies regulatory compliance for multinational corporations seeking to leverage robotic quality inspection capabilities on a global scale.

SHINE Technologies, LLC Announces Submission of FDA Drug Master File for Non-Carrier-Added Lutetium-177

Retrieved on: 
Monday, April 8, 2024
Drug Master File, SHINE, Shine Technologies, Pupa, Patient, Ytterbium, Cancer, Prostate cancer, Cassiopeia, DMF, Food, Pharmaceutical industry

JANESVILLE, Wis., April 8, 2024 /PRNewswire/ -- SHINE Technologies, LLC (SHINE), a pioneer in next-generation fusion-based technology, becomes North America's largest producer of non-carrier added lutetium-177 (n.c.a.

Key Points: 
  • JANESVILLE, Wis., April 8, 2024 /PRNewswire/ -- SHINE Technologies, LLC (SHINE), a pioneer in next-generation fusion-based technology, becomes North America's largest producer of non-carrier added lutetium-177 (n.c.a.
  • Lu-177) chloride, a cutting-edge radiopharmaceutical used in precision cancer treatment, with a Drug Master File (DMF) to the U.S. Food and Drug Administration.
  • The DMF submission provides confidential, detailed information about SHINE's facilities, procedures, and articles utilized in drug manufacturing, processing, and storage.
  • By producing Lu-177 in North America, SHINE reduces transit times companies currently experience and diminishes the possibility of Lu-177's decay.

SHINE Executives to Speak at Fusion Industry Association Annual Conference and CERAWeek Innovation Agora

Retrieved on: 
Tuesday, March 19, 2024
SHINE, FIA, Radel, Conference, Fusion Industry Association, Policy, Shine Technologies, VCS, Lithium

JANESVILLE, Wis., March 19, 2024 /PRNewswire/ -- SHINE Technologies, a next-generation fusion company, announced Greg Piefer, founder and CEO, and Ross Radel, CTO, will present at energy conferences this week: the Fusion Industry Association (FIA) Annual Conference in Washington, D.C., and the CERAWeek Innovation Agora in Houston, Texas.

Key Points: 
  • Sessions at prestigious energy conferences set to drive fusion energy dialogue, reinforcing commitment to commercialization and nuclear waste recycling
    JANESVILLE, Wis., March 19, 2024 /PRNewswire/ -- SHINE Technologies, a next-generation fusion company, announced Greg Piefer, founder and CEO, and Ross Radel, CTO, will present at energy conferences this week: the Fusion Industry Association (FIA) Annual Conference in Washington, D.C., and the CERAWeek Innovation Agora in Houston, Texas.
  • Piefer is invited to speak on the panel Alternative Markets at the Fusion Industry Association (FIA) Conference on March 21 in Washington, D.C.
  • This event brings together policymakers, scientists, researchers and industry leaders to discuss concrete ways to accelerate the path to commercial fusion energy.
  • Radel is invited to present Used Nuclear Fuel Transmutation and Energy Production: SHINE's Fusion Approach on March 20 at CERAWeek Innovation Agora in Houston, Texas.

SHINE Technologies to Exhibit at 7th Annual Theranostics World Congress

Retrieved on: 
Monday, March 18, 2024
SHINE, Shine Technologies, Radiopharmaceutical, Ytterbium, Radiation, Neoplasm, TWC, Cassiopeia, Cancer

JANESVILLE, Wis., March 18, 2024 /PRNewswire/ -- SHINE Technologies, a leader in medical isotope production, will showcase its innovative capabilities for producing non-carrier-added lutetium-177 (n.c.a Lu-177), a radioisotope used in targeted cancer treatments, at the 7th Theranostic World Congress (TWC), March 22-24 in Santiago, Chile. Attendees are invited to visit Booth A13 to learn about SHINE's production capabilities at its Cassiopeia facility.

Key Points: 
  • JANESVILLE, Wis., March 18, 2024 /PRNewswire/ -- SHINE Technologies, a leader in medical isotope production, will showcase its innovative capabilities for producing non-carrier-added lutetium-177 (n.c.a Lu-177), a radioisotope used in targeted cancer treatments, at the 7th Theranostic World Congress (TWC), March 22-24 in Santiago, Chile.
  • Lu-177.
  • Lu-177.
  • SHINE invites attendees to visit Booth A13 to learn more about its industry-leading production capabilities for n.c.a Lu-177.

SHINE Technologies Empowers Students to Transform Lives through Go Baby Go Program

Retrieved on: 
Friday, March 15, 2024
Community, SHINE, Learning, Mentorship, Build, Farm, Partnership, Superintendent, Shine Technologies, Blain's Farm & Fleet, Student, STEM, Disability, Management

The event marked the Build Day of the Go Baby Go program, a national initiative aimed at providing modified ride-on cars to foster independent mobility in young children.

Key Points: 
  • The event marked the Build Day of the Go Baby Go program, a national initiative aimed at providing modified ride-on cars to foster independent mobility in young children.
  • Over the past nine weeks, students from the School District of Janesville, guided by mentors from SHINE Technologies, have collaborated to design and customize vehicles tailored to each child's unique needs.
  • SHINE Technologies and the School District of Janesville joined forces in this innovative partnership with the Go Baby Go program, which underscores the power of applying their STEM skills to real-world applications.
  • "This collaboration with SHINE and the Illinois Spina Bifida Association makes that real-world connection for our students real and tangible.

Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies

Retrieved on: 
Wednesday, March 6, 2024
Alzheimer's disease, Research, Neuron, Cognition, Neuroinflammation, SPARC, Conference, Biomarker, Therapy, EEG, Protein, CSF, SHINE, Publication, Autophagy, Pharmaceutical industry

The three posters, which are listed below, summarize proteomic analyses from the completed SEQUEL and SPARC studies, which were conducted in adults with mild-to-moderate Alzheimer’s disease.

Key Points: 
  • The three posters, which are listed below, summarize proteomic analyses from the completed SEQUEL and SPARC studies, which were conducted in adults with mild-to-moderate Alzheimer’s disease.
  • These posters identify candidate protein biomarkers that correlate with improvements observed in SEQUEL participants treated with CT1812, Cognition’s lead candidate.
  • Pathways identified in these proteomic analyses support a role for CT1812 in modulating Aβ biology and neuroinflammation, among other disease-relevant processes.
  • “Analyses of CSF samples from these studies build on our efforts to identify candidate biomarkers of CT1812 treatment effect,” explained Mary Hamby, Ph.D. , VP of research at Cognition Therapeutics.

SHINE Technologies Selects Deep Isolation as its Technology Provider for High-Level Waste Storage and Disposal

Retrieved on: 
Thursday, March 7, 2024
UNF, Deep geological repository, UCS, Carbon, Universal, Climate change, Nuclear energy, Shine Technologies, HLW, Half-life, SHINE, MOU, Recycling, Partnership, Renewable energy

Under this agreement, SHINE and Deep Isolation will collaborate and exchange critical information for the use of Deep Isolation's Universal Canister System (UCS) and patented directional drilling solution for deep borehole disposal for isolation and management of high-level waste.

Key Points: 
  • Under this agreement, SHINE and Deep Isolation will collaborate and exchange critical information for the use of Deep Isolation's Universal Canister System (UCS) and patented directional drilling solution for deep borehole disposal for isolation and management of high-level waste.
  • The study also identified areas where further technical work could optimize Deep Isolation's technology for the remaining waste, reducing disposal costs even further.
  • Deep Isolation has proven they have a realistic and reasonable solution for the disposal of these wastes, among others as needed.
  • Integrating Deep Isolation's disposal technology with SHINE's recycling technology offers a powerful solution."

Used Nuclear Fuel Recycling Agreement Signed by Orano and SHINE Technologies

Retrieved on: 
Thursday, February 29, 2024
SHINE, MOU, Recycling, Toxicity, Shine Technologies, Pupa, Isotope, CFR, Uranium mining

BETHESDA, Md., Feb. 29, 2024 /PRNewswire/ -- Orano and SHINE Technologies signed a Memorandum of Understanding (MOU) this week to cooperate in the development of a U.S. pilot plant with commercial-scale technology for recycling used nuclear fuel from light water reactors.

Key Points: 
  • BETHESDA, Md., Feb. 29, 2024 /PRNewswire/ -- Orano and SHINE Technologies signed a Memorandum of Understanding (MOU) this week to cooperate in the development of a U.S. pilot plant with commercial-scale technology for recycling used nuclear fuel from light water reactors.
  • "For this initiative with SHINE, we bring more than 55 years of experience transporting and recycling used nuclear fuel in France and managing used fuel in the U.S."
    "Our goal is to stand up an operational pilot facility by the early 2030s.
  • "It is time for the U.S. to seriously consider recycling used nuclear fuel," said Jean-Luc Palayer, CEO of Orano USA.
  • Recycling used nuclear fuel into useful products will significantly reduce the mass, volume, and toxicity of the remaining nuclear material for permanent disposal.

Cognition Therapeutics CEO Issues Letter to Shareholders

Retrieved on: 
Thursday, January 4, 2024
Biology, Work, Geographic atrophy, SHIMMER, Alzheimer's disease, Dementia, Neuron, ACTC, Iris (anatomy), EEG, Lewy body, RPE, Antibody, Letter, AMD, Brain, Therapy, Clinical trial, ADAS, SPARC, Society, DLB, SHINE, Cognition, Vance DeGeneres, Biomarker, Toxicity, Optimism, Manuscript, Cell, Patient, Magnification, Synapse, Diagnosis, Safety, Pharmaceutical industry

PURCHASE, N.Y., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024. The full text of the letter follows:

Key Points: 
  • PURCHASE, N.Y., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024.
  • The full text of the letter follows:
    The year ahead holds great promise for Cognition Therapeutics.
  • As we work towards these important milestones, we take stock of the achievements that give rise to optimism at Cognition Therapeutics and in the broader medical community.
  • For Cognition, expanding the pipeline for CT1812 to dry AMD has the potential to grow Cognition’s value across multiple age-related diseases.